A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma

Phase 2

Terminated

• Conditions: Renal Cell Carcinoma
• Interventions: Biological: Nivolumab; Biological: Ipilimumab

• Registration Number: NCT04088500
• Lead Sponsor: Bristol-Myers Squibb

Brief Summary

The purpose of the study is to assess the effectiveness of re-induction with Nivolumab combined with ipilimumab.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2019-09-10
• Study First Submitted QC: 2019-09-11
• Study First Posted: 2019-09-12
• Study Start: 2020-09-03
• Primary Completion: 2021-11-15
• Study Completion: 2021-11-15
• Results First Submitted: 2022-11-15
• Status Verified: 2022-12
• Results First Submitted QC: 2022-12-15
• Last Update Submitted: 2022-12-15
• Results First Posted: 2023-01-10
• Last Update Posted: 2023-01-10

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

-Participants and Target Disease Characteristics- -

• Confirmed disease progression by RECIST 1.1 criteria on nivolumab maintenance after induction with ipilimumab and nivolumab
• Progress of maintenance treatment of nivolumab by RECIST. Pathology report must be submitted for embedded tissue block or tumor tissue.

Age and Reproduction Sexually active males with WOCBP must agree to instructions for contraception and fetal protection.

WOCBP need to use contraception throughout the study and for 5 months post treatment.

Exclusion Criteria autoimmune disease statement

• Active central nervous system metastases
• Participants with an active autoimmune disease, diabetes mellitus, skin disorders, hyperthyroidism requiring hormone treatments are permitted to enroll.
• Any major surgery 28 days before 1st treatment Concomitant Therapy
• participants that have received a live vaccine within 30 days of treatment.
• use of investigational agent or device with in 28 days before first dosage study treatment.

Physical and Laboratory Test Findings Allergies and Adverse Drug Reaction Age and Reproduction

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Nivolumab + Ipilimumab (combination)	Nivolumab	Nivolumab + Ipilimumab (combination) Q3W for 4 doses
Nivolumab + Ipilimumab (combination)	Ipilimumab	Nivolumab + Ipilimumab (combination) Q3W for 4 doses

Primary Outcome Measures

Name	Time	Method
Disease Control Rate (DCR)	From first dose up to approximately 14 months	Disease Control Rate (DCR) is defined as the percentage of participants who achieve a confirmed best response of complete response (CR), partial response (PR), or stable disease (SD) for at least 6 months after first treatment dose per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.; Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.; Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study.

Secondary Outcome Measures

Name	Time	Method
Overall Survival (OS)	From first dose to the date of death from any cause (up to approximately 14 months)	Overall Survival (OS) is defined as the time from first dose to the date of death from any cause. For participants that are alive, their survival time will be censored at the date of last contact ("last known alive date"). OS will be censored for participants at the date of first dose if they were treated but had no follow-up.
Overall Response Rate (ORR)	From first dose and the date of objectively documented progression criteria or the date of subsequent therapy, whichever occurs first (up to approximately 14 months)	Overall Response Rate (ORR) is defined as the percentage of participants who achieve a best response of complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.; Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.; Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Duration of Response (DOR)	From first dose to the date of the first documented progression or death due to any cause, whichever occurs first (up to approximately 14 months)	Duration of Response (DOR) is defined as the time between the date of first documented response (complete response (CR) or partial response (PR)) to the date of the first documented progression, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, or death due to any cause, whichever occurs first.; Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.; Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time to Objective Response (TTR)	From first dose to the first confirmed documented response (up to approximately 14 months)	Time to Objective Response (TTR) is defined as the time between the date of the first dose and the first confirmed documented response (complete response (CR) or partial response (PR)) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.; Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.; Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Progression Free Survival (PFS)	From first dose to the first date of documented progression or death due to any cause, whichever occurs first (up to approximately 14 months)	Progression Free Survival (PFS) is defined as the time between the date of first dose and the first date of documented progression, as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, or death due to any cause, whichever occurs first. Progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
The Number of Participants Experiencing Adverse Events (AEs)	From first dose and 100 days after lost dose (up to approximately 14 months)	The number of participants with any grade adverse events (AEs). An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

Trial Locations

Locations (9)

Washington University School of Medicine in St. Louis WUSTL; 🇺🇸 Saint Louis, Missouri, United States

Local Institution; 🇨🇦 Quebec City, Quebec, Canada

Cross Cancer Institute; 🇨🇦 Edmonton, Alberta, Canada

Atlantic Clinical Cancer Research Unit; 🇨🇦 Halifax, Nova Scotia, Canada

Hamilton Health Sciences (HHS) - Juravinski Cancer Centre (JCC); 🇨🇦 Hamilton, Ontario, Canada

Toronto Sunnybrook Regional Cancer Ctr; 🇨🇦 Toronto, Ontario, Canada

Local Institution - 0005; 🇨🇦 Montreal, Quebec, Canada

Local Institution - 0006; 🇨🇦 Sherbrooke, Quebec, Canada

BC Cancer Agency - Vancouver Centre; 🇨🇦 Vancouver, British Columbia, Canada